
Figure 1
Direct and indirect interplays between tobacco use, cardiovascular disease, and COVID-19.
| MEASURES | OBJECTIVES |
|---|---|
| Document systematically the use of tobacco and nicotine products in medical records |
|
| Study the interplays between tobacco use, cardiovascular disease, and emerging SARS-CoV-2 variants |
|
| Ensure availability, accessibility, and affordability of tobacco cessation services, including during health emergencies |
|
| Leverage digital health solutions to enhance tobacco cessation services |
|
| MEASURES | OBJECTIVES |
|---|---|
| Accelerate the implementation and expansion of tobacco control policies |
|
| Maintain tobacco control policies instituted during health emergencies |
|
| Prioritise health equity in national pandemic responses |
|
| Implement Article 5.3 of the WHO FCTC* General Obligations: Conflicts of Interests, recognising that there is an irreconcilable conflict between the tobacco industry’s interest and public health policy interest. |
|
| Monitor and oversee the activities of the tobacco industry during health emergencies |
|
| Implement Article 6 of the WHO FCTC* Price and Tax Measures to Reduce the Demand for Tobacco |
|
| Implement Article 8 of the WHO FCTC* Protection from Exposure to Tobacco Smoke |
|
| Implement Article 12 of the WHO FCTC* Education, Communication, Training, and Public Awareness |
|
| Implement Article 14 of the WHO FCTC* Demand Reduction Measures Concerning Tobacco Dependence and Cessation |
|
[i] *Countries that are not signatories to the WHO Framework Convention on Tobacco Control are also able to enact the above measures.
